Line graph illustrating mean random blood glucose (mmol/L) at weekly intervals during the induction phase. by Elsie D. Oduor (22521785)

Subjects:

Mean liver weight (g) (A), liver weight/body ratio (B), hepatic triglyceride (mg/g) (C) and hepatic steatosis quantification (% area) (D) upon completion of the treatment phase. by Elsie D. Oduor (22521785)

Subjects:

Schematic overview of the experimental groups. by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean food intake (in grams) at weekly intervals during the induction phase. by Elsie D. Oduor (22521785)

Subjects:

Mean blood glucose responses (mmol/L) to an oral blood glucose bolus 2g/kg during a 120-minute period and mean area under the curve (mmol/L.min) during the oral blood glucose toler... by Elsie D. Oduor (22521785)

Subjects:

Mean mesenteric, retroperitoneal, pericardial, and total visceral adipose tissue weights (in grams) upon completion of the experiment. by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean body weight (in grams) at weekly intervals during the induction phase. by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean random blood glucose (mmol/L) at weekly intervals during the treatment phase. by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean body weight (in grams) at weekly intervals during the treatment phase. by Elsie D. Oduor (22521785)

Subjects:

Mean lipid profile (mmol/L) upon completion of the experimental period. by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean food intake (g) at weekly intervals during the treatment phase. by Elsie D. Oduor (22521785)

Subjects:

Mean blood glucose responses (mmol/L) to an oral blood glucose bolus 2g/kg during a 120-minute period and mean area under the curve (mmol/L.min) during the oral blood glucose toler... by Elsie D. Oduor (22521785)

Subjects:

Representative liver histology of normal control (A), low-dose Olanzapine (B), negative control (C), test (D), and positive control (E) groups (Hematoxylin and Eosin stain, ×400 ma... by Elsie D. Oduor (22521785)

Subjects:

Chitosan-Based Thermal-Coagulation Hydrogel System Driven by Multiple Interactions: Oxidation-Induced Fast Gelation and Enhanced Performance by Yifan Liu (219681)

Subjects:

Chitosan-Based Thermal-Coagulation Hydrogel System Driven by Multiple Interactions: Oxidation-Induced Fast Gelation and Enhanced Performance by Yifan Liu (219681)

Subjects:

Chitosan-Based Thermal-Coagulation Hydrogel System Driven by Multiple Interactions: Oxidation-Induced Fast Gelation and Enhanced Performance by Yifan Liu (219681)

Subjects:

ROC for Classification of Test Results: (a) ROC Curve of the First Forced Drop-off Decision Models; (b) ROC Curve of the Decision Models for Second and More Forced Parking and Drop... by Fangyi Yang (18867853)

Subjects:

Characteristics of patients with abnormal lung function whose severity classification changed when the <i>z</i>-score guidelines from 2022 were applied in comparison to those who w... by Piotr W. Boros (21446186)

Hazard ratios (HR) for all-cause mortality with 95% confidence intervals from Cox regression models using the 2005 vs. the 2022 guidelines for grading severity, normal FVC (<i>n</i... by Piotr W. Boros (21446186)

In vivo combination activity of AMG 510 and pemigatinib in epithelial-like or mesenchymal-like phenotype lung cancer PDX models. by Angela Abdollahi (15166230)